Cited by 4,110Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and SignalingDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 116 of the 119 references it cites were found in a registry or an index.

Epidemiology of Parkinson's disease

de Lau, Lonneke ML, Breteler, Monique MB·2006·The Lancet Neurology

DOI 10.1016/s1474-4422(06)70471-9

Open this paper in CoChat — free account

Abstract

The causes of Parkinson's disease (PD), the second most common neurodegenerative disorder, are still largely unknown. Current thinking is that major gene mutations cause only a small proportion of all cases and that in most cases, non-genetic factors play a part, probably in interaction with susceptibility genes. Numerous epidemiological studies have been done to identify such non-genetic risk factors, but most were small and methodologically limited. Larger, well-designed prospective cohort studies have only recently reached a stage at which they have enough incident patients and person-years of follow-up to investigate possible risk factors and their interactions. In this article, we review what is known about the prevalence, incidence, risk factors, and prognosis of PD from epidemiological studies.

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(06)70471-9

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
Betarbet, R. S., Sherer, T., MacKenzie, G. M., Garcia‐Osuna, M., Panov, A. V., & Greenamyre, J. T. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,777
Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481
Incidence of Parkinson's Disease: Variation by Age, Gender, and Race/Ethnicity
Eeden, S. K. V. D. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg068 · Cited by 1,805
Prevalence and Characteristics of Dementia in Parkinson Disease
Aarsland, D., Andersen, K., Larsen, J. O., & Lolk, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.3.387 · Cited by 1,403
Alzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351
SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders
Litvan, I., Bhatia, K. P., Burn, D. J., Goetz, C. G., Lang, A. E., McKeith, I. G., Quinn, N. P., Sethi, K. D., Shults, C. W., & Wenning, G. K. (2003) · Movement Disorders · doi:10.1002/mds.10459 · Cited by 1,011
Parkinson Disease in Twins
Tanner, C. M., Ottman, R., Goldman, S. M., Ellenberg, J., Chan, P., Mayeux, R. P., & Langston, J. W. (1999) · JAMA · doi:10.1001/jama.281.4.341 · Cited by 876
Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD)
Defer, G., Widner, H., Mari�, R.-M., Rémy, P., & Levivier, M. (1999) · Movement Disorders · doi:10.1002/1531-8257(199907)14:4 · Cited by 863
The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK
MacDonald, B. K. (2000) · Brain · doi:10.1093/brain/123.4.665 · Cited by 858

Show all 119 references

Research works printed but not linked: 3

Fink, 2001, Caffeine intake and the risk of incident Parkinson's disease: the Framingham Study, Mov Disord, 16, 984
Anderson, 1999, Dietary factors in Parkinson's disease: the role of food groups and specific foods, Mov Disord, 14, 21, 10.1002/1531-8257(199901)14:1<21::AID-MDS1006>3.0.CO;2-Y · DOI
De Lau LM, Koudstaal PJ, Witteman J, Hofman A, Breteler MM. Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease. Neurology (in press).

Sorted by citations

Items 101–200 of 1,019

Motor and non-motor circuit disturbances in early Parkinson disease: which happens first?
Blesa, J., Foffani, G., Dehay, B., Bezard, E., & Obeso, J. A. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00542-9 · Cited by 232
Non-Motor Symptoms in Patients with Parkinson’s Disease – Correlations with Inflammatory Cytokines in Serum
Lindqvist, D., Kaufman, E., Brundin, L., Hall, S., Surova, Y., & Hansson, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047387 · Cited by 236
Case–control association mapping by proxy using family history of disease
Liu, J. Z., Erlich, Y., & Pickrell, J. K. (2017) · Nature Genetics · doi:10.1038/ng.3766 · Cited by 238
Recent advances and perspectives of metabolomics-based investigations in Parkinson’s disease
Shao, Y., & Le, W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0304-2 · Cited by 243
PINK1/Parkin Mediated Mitophagy, Ca2+ Signalling, and ER–Mitochondria Contacts in Parkinson’s Disease
Barazzuol, L., Giamogante, F., Brini, M., & Calí, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051772 · Cited by 246
“Among the total Parkinson′s patients, only 5%–10% are familial—they carry heritable, disease-associated monogenic mutations in genes referred to as the PARK genes [3].”
Background
Outdoor Ambient Air Pollution and Neurodegenerative Diseases: the Neuroinflammation Hypothesis
Jayaraj, R. L., Rodriguez, E. A., Wang, Y., & Block, M. L. (2017) · Current Environmental Health Reports · doi:10.1007/s40572-017-0142-3 · Cited by 240
Deep learning for freezing of gait detection in Parkinson’s disease patients in their homes using a waist-worn inertial measurement unit
Camps, J., Samà, A., Martín, M., Rodríguez-Martín, D., Pérez-López, C., Moreno Arostegui, J. M., Cabestany, J., Català, A., Alcaine, S., Mestre, B., et al. (2018) · Knowledge-Based Systems · doi:10.1016/j.knosys.2017.10.017 · Cited by 224
Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort
Wahlqvist, M. L., Lee, M., Hsu, C.-C., Chuang, S., Lee, J.-T., & Tsai, H.-N. (2012) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.03.010 · Cited by 234
Effects of Repetitive Transcranial Magnetic Stimulation on Motor Symptoms in Parkinson Disease
Chou, Y.-H., Hickey, P., Sundman, M. H., Song, A., & Chen, N. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4380 · Cited by 239
The role of endoplasmic reticulum stress in neurodegenerative disease
Xiang, C., Wang, Y., Zhang, H., & Han, F. (2016) · APOPTOSIS · doi:10.1007/s10495-016-1296-4 · Cited by 235
The critical role of Faecalibacterium prausnitzii in human health: An overview
Leylabadlo, H. E., Ghotaslou, R., Feizabadi, M. M., Farajnia, S., Moaddab, S. Y., Ganbarov, K., Khodadadi, E., Tanomand, A., Sheykhsaran, E., Yousefi, B., et al. (2020) · Microbial Pathogenesis · doi:10.1016/j.micpath.2020.104344 · Cited by 245
Epigenetic targeting of histone deacetylase: Therapeutic potential in Parkinson's disease?
Harrison, I. F., & Dexter, D. T. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.05.010 · Cited by 233
Parkinson’s Disease: A Review from Pathophysiology to Treatment
Marino, B. L. B., de Souza, L. R., Sousa, K. P. A., Ferreira, J. V., Padilha, E. C., da Silva, C. H. T. D. P., Taft, C. A., & Hage-Melim, L. I. D. S. (2019) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557519666191104110908 · Cited by 239
Comprehensive metabolic profiling of Parkinson’s disease by liquid chromatography-mass spectrometry
Shao, Y., Li, T., Liu, Z., Wang, X., Xu, X., Li, S., Xu, G., & Le, W. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00425-8 · Cited by 226
Astrocytes and Therapeutics for Parkinson's Disease
Rappold, P. M., & Tieu, K. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.07.001 · Cited by 234
Exercise for people in early- or mid-stage Parkinson disease: a 16-month randomized controlled trial
Schenkman, M., Hall, D. A., Barón, A. E., Schwartz, R. S., Mettler, P., & Kohrt, W. M. (2012) · Physical Therapy · doi:10.2522/ptj.20110472 · Cited by 224
How many people would benefit from a smart wheelchair?
Simpson, R. C. (2008) · The Journal of Rehabilitation Research and Development · doi:10.1682/jrrd.2007.01.0015 · Cited by 224
“Symptoms of PD include motor abnormalities (tremor, rigidity, bradykinesia, and balance problems) and cognitive impairment [43–44].”
Background
Sirtuin deacetylases in neurodegenerative diseases of aging
Herskovits, A. Z., & Guarente, L. (2013) · Cell Research · doi:10.1038/cr.2013.70 · Cited by 230
Array CGH in patients with learning disability (mental retardation) and congenital anomalies: updated systematic review and meta-analysis of 19 studies and 13,926 subjects
Sagoo, G. S., Butterworth, A. S., Sanderson, S., Shaw-Smith, C. J., Higgins, J. P. T., & Burton, H. (2009) · Genetics in Medicine · doi:10.1097/gim.0b013e318194ee8f · Cited by 228
Control of dopaminergic neuron survival by the unfolded protein response transcription factor XBP1
Valdés, P., Mercado, G., Vidal, R. L., Molina, C., Parsons, G., Court, F. A., Martinez, A. N., Galleguillos, D., Armentano, D., Schneider, B. L., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321845111 · Cited by 220
“Proc Natl Acad Sci USA 105(2):757–762.”
Background
p53‐dependent neuronal cell death in a DJ‐1‐deficient zebrafish model of Parkinson's disease
Bretaud, S., Allen, C. E., Ingham, P. W., & Bandmann, O. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04291.x · Cited by 219
“Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease (de Lau and Breteler 2006).”
Background
Mitochondrial abnormalities in Parkinson's disease and Alzheimer's disease: can mitochondria be targeted therapeutically?
Macdonald, R., Barnes, K., Hastings, C., & Mortiboys, H. (2018) · Biochemical Society Transactions · doi:10.1042/bst20170501 · Cited by 223
Physical exercise for people with Parkinson’s disease: a systematic review and network meta-analysis
Ernst, M., Folkerts, A., Gollan, R., Lieker, E., Caro-Valenzuela, J., Adams, A., Cryns, N., Monsef, I., Dresen, A., Roheger, M., et al. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013856.pub2 · Cited by 251
Brain mechanisms of acoustic communication in humans and nonhuman primates: An evolutionary perspective
Ackermann, H., Hage, S. R., & Ziegler, W. (2014) · Behavioral and Brain Sciences · doi:10.1017/s0140525x13003099 · Cited by 224
Medical Management of Levodopa-Associated Motor Complications in Patients with Parkinson???s Disease
Jankovic, J. J., & Stacy, M. A. (2007) · CNS Drugs · doi:10.2165/00023210-200721080-00005 · Cited by 214
The Role of the Gastrointestinal Mucus System in Intestinal Homeostasis: Implications for Neurological Disorders
Herath, M., Hosie, S., Bornstein, J. C., Franks, A. E., & Hill‐Yardin, E. L. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00248 · Cited by 236
Nigral pathology and parkinsonian signs in elders without Parkinson disease
Buchman, A. S., Shulman, J. M., Nag, S., Leurgans, S. E., Arnold, S. E., Morris, M. C., Schneider, J. A., & Bennett, D. A. (2011) · Annals of Neurology · doi:10.1002/ana.22588 · Cited by 220
Deep representation learning of electronic health records to unlock patient stratification at scale
Landi, I., Glicksberg, B. S., Lee, H.-C., Cherng, S., Landi, G., Danieletto, M., Dudley, J. T., Furlanello, C., & Miotto, R. (2020) · npj Digital Medicine · doi:10.1038/s41746-020-0301-z · Cited by 213
“, averaged increased prevalence after 60 years of age) [26, 27, 28, 29, 30, 31].”
BackgroundInfluential
Orthostatic Hypotension-Related Hospitalizations in the United States
Shibao, C. A., Grijalva, C. G., Raj, S. R., Biaggioni, I., & Griffin, M. R. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.05.009 · Cited by 212
Endocannabinoid system in neurodegenerative disorders
Basavarajappa, B. S., Shivakumar, M., Joshi, V., & Subbanna, S. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14098 · Cited by 222
“The irreversible loss of the DA-mediated control of striatal function leads to bradykinesia, tremor, and rigidity in PD (de Lau and Breteler 2006; Branchi et al. 2008, 2010; Bartels and Leenders 2009).”
Background
Mercury Involvement in Neuronal Damage and in Neurodegenerative Diseases
Cariccio, V. L., Samà, A., Bramanti, P., & Mazzon, E. (2018) · Biological Trace Element Research · doi:10.1007/s12011-018-1380-4 · Cited by 246
Understanding the role of histone deacetylase and their inhibitors in neurodegenerative disorders: current targets and future perspective
Kumar, V., Kundu, S., Singh, A., & Singh, S. (2022) · Current Neuropharmacology · doi:10.2174/1570159x19666210609160017 · Cited by 210
Mutations for Gaucher Disease Confer High Susceptibility to Parkinson Disease
Mitsui, J., Mizuta, I., Toyoda, A., Ashida, R., Takahashi, Y., Goto, J., Fukuda, Y., Date, H., Iwata, A., Yamamoto, M., et al. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.72 · Cited by 213
Walking in fully immersive virtual environments: an evaluation of potential adverse effects in older adults and individuals with Parkinson’s disease
Kim, A., Darakjian, N., & Finley, J. M. (2017) · Journal of NeuroEngineering and Rehabilitation · doi:10.1186/s12984-017-0225-2 · Cited by 213
Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA)
Ho, P. W., Leung, C.-T., Liu, H., Pang, S. Y.-Y., Lam, C. S.-C., Xian, J., Li, L., Kung, M. H.-W., Ramsden, D. B., & Ho, S. (2019) · Autophagy · doi:10.1080/15548627.2019.1603545 · Cited by 215
Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases?
Du, X., & Pang, T. Y. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00032 · Cited by 221
Dopamine and Levodopa Prodrugs for the Treatment of Parkinson’s Disease
Haddad, F., Sawalha, M., Khawaja, Y., Najjar, A., & Karaman, R. (2017) · Molecules · doi:10.3390/molecules23010040 · Cited by 223
Noradrenergic Modulation of Cognition in Health and Disease
Borodovitsyna, O., Flamini, M. D., & Chandler, D. J. (2017) · Neural Plasticity · doi:10.1155/2017/6031478 · Cited by 227
Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis
Gao, L., Tang, H., Nie, K., Wang, L., Zhao, J., Gan, R., Huang, J., Zhu, R., Feng, S., Duan, Z., et al. (2014) · International Journal of Neuroscience · doi:10.3109/00207454.2014.961454 · Cited by 210
Sex: A Significant Risk Factor for Neurodevelopmental and Neurodegenerative Disorders
Pinares-Garcia, P., Stratikopoulos, M., Zagato, A., Loke, H., & Lee, J. (2018) · Brain Sciences · doi:10.3390/brainsci8080154 · Cited by 200
Resveratrol protects dopaminergic neurons in midbrain slice culture from multiple insults
Okawara, M., Katsuki, H., Kurimoto, E., Shibata, H., Kume, T., & Akaike, A. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.11.003 · Cited by 202
“Accumulating evidence indicates that multiple factors, including genetic and environmental ones, contribute to acceleration of dopaminergic neurodegeneration in this neurological disorder [1].”
Background
The Spectrum of Parkinsonian Manifestations Associated With Glucocerebrosidase Mutations
Göker-Alpan, Ö., Lopez, G. J., Vithayathil, J., Davis, J., Hallett, M., & Sidransky, E. (2008) · Archives of Neurology · doi:10.1001/archneur.65.10.1353 · Cited by 197
Inflammation in Parkinson's Disease
Tüfekçi, K. U., Meuwissen, R. L. J., Genç, Ş., & Genç, K. (2012) · Advances in protein chemistry and structural biology · doi:10.1016/b978-0-12-398314-5.00004-0 · Cited by 205
Incidence and Pathology of Synucleinopathies and Tauopathies Related to Parkinsonism
Savica, R., Grossardt, B. R., Bower, J. H., Ahlskog, J. E., & Rocca, W. A. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.114 · Cited by 196
A further update on the role of excitotoxicity in the pathogenesis of Parkinson’s disease
Ambrosi, G., Cerri, S., & Blandini, F. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-013-1149-z · Cited by 195
Progress in Parkinson's disease—Where do we stand?
Toulouse, A., & Sullivan, A. M. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.05.003 · Cited by 197
Decision Support Framework for Parkinson’s Disease Based on Novel Handwriting Markers
Drotár, P., Mekyska, J., Rektorová, I., Masárová, L., Smékal, Z., & Faúndez-Zanuy, M. (2014) · IEEE Transactions on Neural Systems and Rehabilitation Engineering · doi:10.1109/tnsre.2014.2359997 · Cited by 195
“usually affects people at an average age of 60 [2], and preva-”
Background
Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target
Cassano, T., Calcagnini, S., Pace, L., Marco, F. D., Romano, A., & Gaetani, S. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00030 · Cited by 200
MiR‐124 Regulates Apoptosis and Autophagy Process in MPTP Model of Parkinson's Disease by Targeting to Bim
Wang, H., Ye, Y., Zhu, Z., Mo, L., Lin, C., Wang, Q., Wang, H., Gong, X., He, X., Lu, G., et al. (2016) · Brain Pathology · doi:10.1111/bpa.12267 · Cited by 198
Vascular Degeneration in Parkinson's Disease
Guan, J., Pavlovic, D., Dalkie, N., Waldvogel, H. J., O'Carroll, S. J., Green, C. R., & Nicholson, L. F. B. (2013) · Brain Pathology · doi:10.1111/j.1750-3639.2012.00628.x · Cited by 191
LRRK2 Gly2019Ser penetrance in Arab–Berber patients from Tunisia: a case-control genetic study
Hulihan, M., Ishihara-Paul, L., Kachergus, J. M., Warren, L. L., Amouri, R., Elango, R., Prinjha, R. K., Upmanyu, R., Kefi, M., Zouari, M., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70116-9 · Cited by 191
SIRT1 ameliorates oxidative stress induced neural cell death and is down-regulated in Parkinson’s disease
Singh, P., Hanson, P. S., & Morris, C. M. (2017) · BMC Neuroscience · doi:10.1186/s12868-017-0364-1 · Cited by 193
Parkinson’s disease and intensive exercise therapy—A systematic review and meta-analysis of randomized controlled trials
Uhrbrand, A., Stenager, E., Pedersen, M. S., & Dalgas, U. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2015.04.004 · Cited by 190
“This is of importance, given the observed natural deterioration, due to the disease [3].”
Background
Association between cigarette smoking and Parkinson’s disease: A meta-analysis
Li, X., Li, W., Liu, G., Shen, X., & Tang, Y. (2015) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2015.08.004 · Cited by 190
Gene–environment interactions in Parkinson's disease: Specific evidence in humans and mammalian models
Cannon, J. R., & Greenamyre, J. T. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.06.025 · Cited by 194
Visualization of monoaminergic neurons and neurotoxicity of MPTP in live transgenic zebrafish
Wen, L., Wei, W., Gu, W., Huang, P., Ren, X., Zhang, Z., Zhu, Z., Lin, S., & Zhang, B. (2007) · Developmental Biology · doi:10.1016/j.ydbio.2007.11.012 · Cited by 189
Human autologous iPSC–derived dopaminergic progenitors restore motor function in Parkinson’s disease models
Song, B., Cha, Y., Ko, S., Jeon, J., Lee, N., Seo, H., Park, K., Lee, I., Lopes, C., Feitosa, M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci130767 · Cited by 195
“evidenced by (1) staining with antibodies against the three germ layer markers and (2) gene expression of lineage-specific markers (Figure 2, C and D).”
BackgroundInfluential
Isradipine Versus Placebo in Early Parkinson Disease
The Parkinson Study Group STEADY-PD III Investigators* (2020) · Annals of Internal Medicine · doi:10.7326/m19-2534 · Cited by 189
An ERcentric view of Parkinson's disease
Mercado, G., Valdés, P., & Hetz, C. A. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.12.005 · Cited by 193
Progression of motor symptoms in Parkinson’s disease
Xia, R., & Mao, Z. (2012) · Neuroscience Bulletin · doi:10.1007/s12264-012-1050-z · Cited by 186
“[4] de Lau LM, Breteler MM.”
Trajectories of prediagnostic functioning in Parkinson’s disease
Darweesh, S. K. L., Verlinden, V. J. A., Stricker, B. H. C., Albert Hofman, D., Koudstaal, P. J., & Ikram, M. A. (2016) · Brain · doi:10.1093/brain/aww291 · Cited by 186
NLRP3 expression in mesencephalic neurons and characterization of a rare NLRP3 polymorphism associated with decreased risk of Parkinson’s disease
von Herrmann, K. M., Salas, L. A., Martinez, E. M., Young, A. L., Howard, J. M., Feldman, M. S., Christensen, B. C., Wilkins, O. M., Lee, S., Hickey, W. F., et al. (2018) · npj Parkinson s Disease · doi:10.1038/s41531-018-0061-5 · Cited by 190
Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice
Rommelfanger, K. S., Edwards, G. L., Freeman, K. G., Liles, L. C., Miller, G. W., & Weinshenker, D. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702753104 · Cited by 184
Differential Effects of Black versus Green Tea on Risk of Parkinson's Disease in the Singapore Chinese Health Study
Tan, L. C. S., Koh, W., Yuan, J., Wang, R., Au, W., Tan, J.-H., Tan, E., & Yu, M. C. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm338 · Cited by 190
“In most studied populations, Parkinson’s disease rates among women are lower than those among men of similar ages ( 1 ).”
BackgroundInfluential
Effects of in vivo conditions on amyloid aggregation
Owen, M. C., Gnutt, D., Gao, M., Wärmländer, S. K. T. S., Jarvet, J., Gräslund, A., Winter, R., Ebbinghaus, S., & Strodel, B. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00034d · Cited by 181
Prospective study of coffee consumption and risk of Parkinson’s disease
Sääksjärvi, K., Knekt, P., Rissanen, H., Laaksonen, M. A., Reunanen, A., & Männistö, S. (2008) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1602788 · Cited by 182
Fluorescent probes for bioimaging of potential biomarkers in Parkinson's disease
Gao, L., Wang, W., Wang, X., Yang, F., Xie, L., Shen, J., Brimble, M. A., Xiao, Q., & Yao, S. Q. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00115e · Cited by 184
Epidemiology of aging and associated cognitive disorders: Prevalence and incidence of Alzheimer's disease and other dementias
López, O. L., & Kuller, L. H. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804766-8.00009-1 · Cited by 196
PD Disease State Assessment in Naturalistic Environments Using Deep Learning
Hammerla, N., Fisher, J., Andras, P., Rochester, L., Walker, R., & Ploetz, T. (2015) · Proceedings of the AAAI Conference on Artificial Intelligence · doi:10.1609/aaai.v29i1.9484 · Cited by 179
Genetics and genomics of Parkinson’s disease
Lin, M. K., & Farrer, M. J. (2014) · Genome Medicine · doi:10.1186/gm566 · Cited by 183
Role of MicroRNAs in Parkinson’s Disease
Goh, S. Y., Chao, Y., Dheen, S. T., Tan, E., & Tay, S. S. W. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225649 · Cited by 179
“An estimated prevalence of 1% of people above 60 years old suffer from PD [1].”
Background
Neuroprotective Effects of Resveratrol on MPTP-Induced Neuron Loss Mediated by Free Radical Scavenging
Lu, K., Ko, M.-C., Chen, B.-Y., Huang, J.-C., Hsieh, C., Lee, M.-C., Chiou, R. Y. ‐., Wung, B., Peng, C.-H., & Yang, Y.-L. (2008) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf8007212 · Cited by 178
Mitochondrial dynamics in Parkinson's disease: a role for α-synuclein?
Devoto, V. M. P., & Falzone, T. L. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.026294 · Cited by 184
Computer-Aided diagnosis of Parkinson’s Disease Using Enhanced Probabilistic Neural Network
Hirschauer, T. J., Adeli, H., & Buford, J. A. (2015) · Journal of Medical Systems · doi:10.1007/s10916-015-0353-9 · Cited by 177
Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair
Rothfuss, O. C., Fischer, H., Hasegawa, T., Maisel, M., Leitner, P., Miesel, F., Sharma, M., Bornemann, A., Berg, D., Gasser, T., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp327 · Cited by 182
“More than 1% of subjects older than 60 years are affected by PD (1).”
Background
Diagnosis of Parkinson's Disease Based on Disease-Specific Autoantibody Profiles in Human Sera
Han, M. C., Nagele, E. P., DeMarshall, C. A., Acharya, N. K., & Nagele, R. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032383 · Cited by 179
DNA methylation, a hand behind neurodegenerative diseases
Lu, H., Liu, X., Yu-Lin, D. E. N. G., & Qing, H. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00085 · Cited by 181
α-synuclein aggregation and its modulation
Ghosh, D., Mehra, S., Sahay, S., Singh, P. K., & Maji, S. K. (2016) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2016.10.021 · Cited by 193
Early predictors of mortality in parkinsonism and Parkinson disease
Bäckström, D. C., Granåsen, G., Domellöf, M., Linder, J., Mo, S. J., Riklund, K., Zetterberg, H., Blennow, K., & Forsgren, L. (2018) · Neurology · doi:10.1212/wnl.0000000000006576 · Cited by 188
Factors Associated With Exercise Behavior in People With Parkinson Disease
Ellis, T. D., Cavanaugh, J. T., Earhart, G. M., Ford, M. P., Foreman, K. B., Fredman, L., Boudreau, J. K., & Dibble, L. E. (2011) · Physical Therapy · doi:10.2522/ptj.20100390 · Cited by 181
Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease
Sgambato, V., & Cenci, M. A. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.10.005 · Cited by 175
Epidemiology of neurological diseases in older adults
Dumurgier, J., & Tzourio, C. (2020) · Revue Neurologique · doi:10.1016/j.neurol.2020.01.356 · Cited by 183
The Roc domain of leucine‐rich repeat kinase 2 is sufficient for interaction with microtubules
Gandhi, P. N., Wang, X., Zhu, X., Chen, S. G., & Wilson‐Delfosse, A. L. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21622 · Cited by 168
Deep brain stimulation in Parkinson disease: a metaanalysis of patient outcomes
Weaver, F. M., Follett, K. A., Hur, K., Ippolito, D., & Stern, M. (2005) · Journal of neurosurgery · doi:10.3171/jns.2005.103.6.0956 · Cited by 168
Calcium entry induces mitochondrial oxidant stress in vagal neurons at risk in Parkinson's disease
Goldberg, J. A., Guzmán, J. N., Estep, C. M., Ilijić, E., Kondapalli, J., Sánchez-Padilla, J., & Surmeier, D. J. (2012) · Nature Neuroscience · doi:10.1038/nn.3209 · Cited by 167
Melatonin or silymarin reduces maneb‐ and paraquat‐induced Parkinson’s disease phenotype in the mouse
Singhal, N. K., Srivastava, G., Patel, D. K., Jain, S. K., & Singh, M. P. (2010) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2010.00819.x · Cited by 166
C9orf72 repeat expansions are a rare genetic cause of parkinsonism
Lesage, S., Le Ber, I., Condroyer, C., Broussolle, E., Gabelle, A., Thobois, S., Pasquier, F., Mondon, K., Dion, P. A., Rochefort, D., et al. (2013) · Brain · doi:10.1093/brain/aws357 · Cited by 164
“The prevalence of this condition is age-dependent, affecting more than 1% of persons over the age of 65 years, but this rate is increased to 4-5 % by the age of 85 years (De Lau and Breteler, 2006).”
Background
Oxidation of the cysteine-rich regions of parkin perturbs its E3 ligase activity and contributes to protein aggregation
Meng, F., Yao, D., Shi, Y., Kabakoff, J., Wu, W., Reicher, J. J., Ma, Y., Moosmann, B., Masliah, E., Lipton, S. A., et al. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-34 · Cited by 172
A systematic review of the worldwide prevalence and incidence of Parkinson's disease.
Muangpaisan, W., Mathews, A., Hori, H., & Seidel, D. (2011) · PubMed · Cited by 165
A process-model based approach to prospective memory impairment in Parkinson's disease
Kliegel, M., Altgassen, M., Hering, A., & Rose, N. S. (2011) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2011.01.024 · Cited by 163
Reprint of: Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease—resemblance to the effect of amphetamine drugs of abuse
Perfeito, R., Cunha‐Oliveira, T., & Rego, A. C. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.05.042 · Cited by 169
Characterization of Retinal Microvascular and Choroidal Structural Changes in Parkinson Disease
Robbins, C. B., Thompson, A. C., Bhullar, P. K., Koo, H. Y., Agrawal, R. V., Soundararajan, S., Yoon, S. P., Polascik, B. W., Scott, B. L., Grewal, D. S., et al. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.5730 · Cited by 163
The P2X7 Receptor: Central Hub of Brain Diseases
Andrejew, R., Oliveira-Giacomelli, Á., Ribeiro, D. E., Glaser, T., Arnaud-Sampaio, V. F., Lameu, C., & Ulrich, H. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00124 · Cited by 162
Role of DaTSCAN and clinical diagnosis in Parkinson disease
de la Fuente‐Fernández, R. (2012) · Neurology · doi:10.1212/wnl.0b013e318248e520 · Cited by 162
Pathological correlations between traumatic brain injury and chronic neurodegenerative diseases
Cruz-Haces, M., TANG, J. C. Y., Acosta, G., Fernandez, J., & Shi, R. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0088-2 · Cited by 166
The Effects of Omega-3 Fatty Acids and Vitamin E Co-Supplementation on Clinical and Metabolic Status in Patients with Parkinson’s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
Taghizadeh, M., Tamtaji, O. R., Dadgostar, E., Daneshvar Kakhaki, R., Bahmani, F., Abolhassani, J., Aarabi, M. H., Kouchaki, E., Memarzadeh, M. R., & Asemi, Z. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.03.014 · Cited by 162
Genetic deficiency of the mitochondrial protein PGAM5 causes a Parkinson’s-like movement disorder
Lü, W., Karuppagounder, S. S., Springer, D., Allen, M. D., Zheng, L., Chao, B. N., Zhang, Y., Dawson, V. L., Dawson, T. M., & Lenardo, M. J. (2014) · Nature Communications · doi:10.1038/ncomms5930 · Cited by 162
Exosomes and stem cells in degenerative disease diagnosis and therapy
Chang, Y.-H., Wu, K.-C., Harn, H.-J., Lin, S.-Z., & Ding, D.-C. (2018) · Cell Transplantation · doi:10.1177/0963689717723636 · Cited by 159
Comprehensive urinary metabolomic profiling and identification of potential noninvasive marker for idiopathic Parkinson’s disease
Luan, H., Liu, L., Tang, Z., Zhang, M., Chua, K.-K., Song, J., Mok, V., Li, M., & Cai, Z. (2015) · Scientific Reports · doi:10.1038/srep13888 · Cited by 157
Glial phagocytic clearance in Parkinson’s disease
Tremblay, M.-E., Cookson, M. R., & Civiero, L. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0314-8 · Cited by 152

Authors: de Lau, L. M., & Breteler, M. M.
Affiliations: Erasmus MC (NL)
Corresponding author: Breteler, Monique MB
ORCID: Breteler, Monique MB
Venue: The Lancet Neurology
Publisher: Elsevier BV
Published: 2006-06
Volume: 5
Issue: 6
Pages: 525-535
ISSN: 1474-4422 (ISSN-L)
DOI: 10.1016/s1474-4422(06)70471-9
OpenAlex: W2134886133
Cited by: 4,110
References: 119
Citations by year: 2026: 108 · 2025: 172 · 2024: 229 · 2023: 230 · 2022: 307 · 2021: 315 · 2020: 337 · 2019: 290 · 2018: 301 · 2017: 284 · 2016: 259 · 2015: 288 · 2014: 232 · 2013: 200 · 2012: 159
FWCI: 7.02
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet Neurology (publishedVersion)
PubMed (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: Parkinson's disease, prevalence, incidence, risk factors, prognosis, genetic susceptibility, gene-environment interaction, neurodegeneration, prospective cohort
MeSH terms: Age Factors, Humans, Parkinson Disease, Prognosis, Risk Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Epidemiology of Parkinson's disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks